Details of the Drug Pharmacogenomic Perturbation Atlas

Rimantadine Drug Info

Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID

5071

ChEBI ID

CHEMBL959

CAS Number

CAS 13392-28-4

TTD Drug ID

D0TQ1G

VARIDT Drug ID

DR00832

INTEDE Drug ID

DR2305

ACDINA Drug ID

D00596

General Information of Drug (ID: DM5DWMU)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Oxidative phosphorylation	2.00	0.00e+0	93/133 (69.92%)	ATP6V1D;ATP5F1E;NDUFA3;...
Phagosome	1.76	4.43e-2	118/152 (77.63%)	HLA-DRA;ATP6V1D;CD14;...
Arginine biosynthesis	-1.74	4.57e-2	17/22 (77.27%)	GLS2;ASL;GLS;...
Glycine, serine and threonine metabolism	-1.84	2.12e-2	31/40 (77.5%)	SDS;BHMT;AGXT;...
Ascorbate and aldarate metabolism	-1.85	2.82e-2	15/30 (50%)	ALDH2;AKR1A1;UGT2A3;...
Cysteine and methionine metabolism	-1.94	8.46e-3	43/50 (86%)	MPST;AHCYL2;DNMT3B;...
Sulfur metabolism	-1.96	1.69e-2	9/10 (90%)	MPST;PAPSS1;PAPSS2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colon carcinoma

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Colorectal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCT 116 (Parent)	CVCL_0291	Homo sapiens	0.04uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	20uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H